-+ 0.00%
-+ 0.00%
-+ 0.00%

Lantern Pharma's Subsidiary, Starlight Therapeutics, Receives FDA Clearance for Phase Ib/2a Clinical Trial in Glioblastoma Multiforme Treatment

Reuters·08/06/2025 12:30:53

Please log in to view news